Val247Leu beta2-glycoprotein-I allelic variant is associated with antiphospholipid syndrome: Systematic review and meta-analysis

Abstract

[EN] Previous studies have suggested that the possession of the Val/Val genotype of the Val247Leu polymorphism of the β2-glycoproteinI (β2-GPI) gene may be associated with antiphospholipid syndrome (APS), and, among patients with APS, with the production of anti-β2-GPI antibodies or the development of thrombosis. Given the controversial results reported, the aim of this work is to combine previous findings by means of a systematic review and a meta-analysis. Methods: We retrieved studies analyzing the genotype of the above-mentioned polymorphism among patients with APS by means of electronic database search. A meta-analysis was conducted in a random effects model and calculations of odds ratio (OR) and confidence intervals (CI) were done. Sensitivity analysis and tests for heterogeneity of the results were performed. Results: Eight previous studies analyzed the association of APS, anti-β2-GPI antibodies and/or thrombosis with the Val247Leu polymorphism. After meta-analysis, patients with APS had a significantly higher prevalence of the Val/ Val genotype of this genetic variant when compared with controls (OR=2.04; 95% CI: 1.12, 3.73; P=0.02). Among patients with APS, those with anti-β2-GPI antibodies had a higher prevalence of this genotype (OR=1.73; 95% CI: 1.04, 2.87; P=0.03). No significant results were found for the presence of arterial or venous thrombosis. Conclusions: Val/Val genotype of β2-GPI gene is associated with a significant excess risk to suffer from APS and, among patients with APS, to have anti-β2-GPI antibodies. No definite conclusions can be made regarding the association of this polymorphism with thrombosis among APS patients. © 20